Krystal Biotech
NEWS
The 2022 American Academy of Dermatology Annual Meeting saw several milestones for treatment explorations for inflammatory diseases. Here is some of the major news:
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
Results from its GEM-3 trial on VYJUVEK demonstrated statistical significance in its ability to promote complete wound healing within six months compared to a placebo.
Yet another busy week for clinical trial news. Here’s a look.
On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech has launched subsidiary Jeune Inc. to promote its gene therapies for aesthetic skin conditions.
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
Biopharma and life sciences strengthen their executive leadership teams and boards with this week’s Movers & Shakers.
JOBS
IN THE PRESS